{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:24:20Z","timestamp":1791498260991,"version":"4.3.4"},"reference-count":24,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the cancer population, patients diagnosed with venous thromboembolism (VTE) are considered to have a threefold increased risk of mortality compared with those without VTE. With the advent of modern computed tomography (CT), the rate of diagnosis of subsegmental pulmonary embolism (SSPE) has increased, likely as a result of improved visualization of the peripheral pulmonary arteries. The clinical significance of SSPE remains unclear because of the lack of randomized controlled clinical trials. The aim of this study was to identify the incidence and risk factors of recurrent proximal PE within 12 months of diagnosis of SSPE in cancer. We performed a retrospective analysis of 206 adult cancer patients who were diagnosed with SSPE from 2014 to 2016 at the University of Texas MD Anderson Cancer Center. At the time of SSPE diagnosis, the majority had metastatic cancer, 108 patients (53.2%) were undergoing chemotherapy, and 23 patients (11.2%) had a history of VTE. Most patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Sixty-seven percent of SSPE was discovered incidentally on restaging CT scans, with the majority being a single and isolated event (70.9%). Within 12 months of SSPE diagnosis, 18 patients (8.7%) were found to have a recurrent PE. The patients treated with anticoagulation had a lower rate of PE recurrence (8% vs 13% in those not treated with anticoagulation). Treatment with anticoagulation did not appear to have a significant impact on overall survival (P = .48) when adjusted for ECOG performance status and cancer stage.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003136","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T18:48:15Z","timestamp":1613846895000},"page":"1050-1058","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-0431","authenticated-orcid":false,"given":"Melissa","family":"Yan","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Melvin Bren and Simon Cancer Center, Indianapolis, IN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Kieser","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Houston Methodist Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol C.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Imaging,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences, Department of Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3929","authenticated-orcid":false,"given":"Cristhiam M.","family":"Rojas-Hernandez","sequence":"additional","affiliation":[{"name":"Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"3","key":"2021021816333229200_B1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11606-006-0019-x","article-title":"The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients","volume":"22","author":"Gross","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"8","key":"2021021816333229200_B2","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1538-7836.2010.03938.x","article-title":"Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies","volume":"8","author":"Carrier","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2021021816333229200_B3","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1001\/jama.1990.03440200057023","article-title":"Value of the ventilation\/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)","volume":"263","author":"PIOPED Investigators","year":"1990","journal-title":"JAMA"},{"issue":"5","key":"2021021816333229200_B4","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1378\/chest.111.5.1246","article-title":"Prevalence of acute pulmonary embolism in central and subsegmental pulmonary arteries and relation to probability interpretation of ventilation\/perfusion lung scans","volume":"111","author":"Stein","year":"1997","journal-title":"Chest"},{"issue":"9148","key":"2021021816333229200_B5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0140-6736(98)05248-9","article-title":"Non-invasive diagnosis of venous thromboembolism in outpatients","volume":"353","author":"Perrier","year":"1999","journal-title":"Lancet"},{"key":"2021021816333229200_B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/asheducation-2017.1.121","article-title":"Incidental venous thromboembolism: is anticoagulation indicated?","volume":"2017","author":"Di Nisio","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2021021816333229200_B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jth.13172","article-title":"Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients","volume":"14","author":"van der Hulle","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2021021816333229200_B8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/acem.13399","article-title":"Systematic review and meta-analysis of outcomes of patients with subsegmental pulmonary embolism with and without anticoagulation treatment","volume":"25","author":"Bariteau","year":"2018","journal-title":"Acad Emerg Med"},{"key":"2021021816333229200_B9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejim.2019.10.033","article-title":"Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American Society of Clinical Oncology","volume":"71","author":"Verso","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2021021816333229200_B10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11239-014-1143-9","article-title":"Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties","volume":"40","author":"Lim","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2021021816333229200_B11","doi-asserted-by":"crossref","first-page":"W7","DOI":"10.1097\/RTI.0000000000000048","article-title":"Computed tomography and echocardiography in patients with acute pulmonary embolism: part 2: prognostic value","volume":"29","author":"George","year":"2014","journal-title":"J Thorac Imaging"},{"key":"2021021816333229200_B12","first-page":"2119","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","author":"Kaatz","year":"2015"},{"key":"2021021816333229200_B13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CEOR.S39964","article-title":"Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States","volume":"5","author":"Khorana","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"issue":"20","key":"2021021816333229200_B14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021021816333229200_B15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/annonc\/mdq720","article-title":"Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients","volume":"22","author":"Font","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"2021021816333229200_B16","first-page":"JCO1901461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"15","author":"Key","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"2021021816333229200_B17","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2021021816333229200_B18","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2021021816333229200_B19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2021021816333229200_B20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2021021816333229200_B21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2021021816333229200_B22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2021021816333229200_B23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"2021021816333229200_B24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/4\/1050\/1800634\/advancesadv2020003136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/4\/1050\/1800634\/advancesadv2020003136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T18:48:34Z","timestamp":1613846914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/4\/1050\/475234\/Clinical-factors-and-outcomes-of-subsegmental"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003136","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}